RxDoctor Payments Data

Samuel Patton, MD

Otolaryngology · Houston, TXNPI 1861711186

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 54.8% of the total. Reporting peaked in 2023 at $551 and has fallen 93.1% since, to $38 in 2025. That places this record below the midpoint for otolaryngology clinicians in TX, where the typical reported total is $1,798.

$1,546in general payments, 2019–2025

Across 59 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$847
  • Optinose US, Inc.$289
  • Stryker$107
  • Aerin Medical Inc.$105
  • Medtronic$48
  • Sanofi$23
  • plus $126 from 7 others
$15,402in research payments, 2019–2025

Across 1 payment — averaging $15,402 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$15K

What the payments were for

  • Food & beverage$1,546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,546 in reported general payments places this provider in the 45th percentile of 729 otolaryngology providers in Texas.

See all otolaryngology providers in Texas →

Medicare billing

Part B allowed, 2024
$210,523
Medicare patients
439
Services billed
1,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide144$4,150
Azelastine Hcl76$3,411
Fluocinolone Acetonide Oil35$1,334
Fluticasone Propionate41$919
Ofloxacin20$604
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort12$591
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav70$562
Doxycycline Hyclate57$509
Famotidine60$408
Cefdinir21$267
Gabapentin17$256
Methylprednisolone43$210
Mupirocin24$143
Prednisone17$31

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →